Acute myeloid leukemia non m3. Acute myeloblastic leukemia
Conditions
Interventions
Intervention 1: Intervention group: the group that receives sodium valproate 200 mg three times a day from day 1 to day 28 of treatment plus cytarabine regimen 20 mg/m2 twice a day from day 1 to day 1
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: age more than 60 year with AML NON M3 normal liver function test normal ECG
Exclusion criteria
Exclusion criteria: sever liver disease and abnormal liver function test history depression and suiside history allergy to valproat sodium history use of anticonvulsion drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to cytarabine and sodium valproate regimen treatment after three treatment cycles based on bone marrow sampling as complete response, partial response or non-response to treatment. Timepoint: Evaluation bone marrow blast befor start of treatment and after three cycles treatment. Method of measurement: evaluation Pathology and/or flow cytometry examination of bone marrow biopsy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation platelet and befor and after any treatment cycle. Timepoint: At the beginning of the intervention and on day 10,17 and 24 during the intervention. Method of measurement: Complete blood count differential.;Sepsis. Timepoint: At the beginning of the intervention and on day 10,17 and 24 during the intervention. Method of measurement: Clinical examination and fever chart, in case of positive blood culture.;Evaluation neutrophils before and after any treatment cycle. Timepoint: At the beginning of the intervention and on day 10,17 and 24 during the intervention. Method of measurement: Complete blood count differential. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein asgharipour
Shahid Beheshti University of Medical Sciences
Outcome results
None listed